{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011550","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.557506+00:00","generated_at":"2026-06-13T14:34:29.673917+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Protalix adjourns annual meeting to solicit votes for authorized share increase to 185M","bullets":["Meeting approved election of 7 directors; votes ranged from 30.1M to 30.7M for, 2.2M to 2.7M withheld.","Stock plan amendment approved: shares available increased from 8.475M to 12.475M (25.8M for, 6.9M against).","Advisory vote on say-on-pay frequency favored one year (30.3M votes); board adopts annual frequency.","Meeting adjourned to July 13, 2023 to solicit more votes for charter amendment increasing authorized shares from 144M to 185M.","Ratification of PwC as auditor approved with 36.8M for, 2.7M against; broker non-votes existed on other items."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011550","json":"https://secwatch.observer/filing/0001558370-23-011550.json","markdown":"https://secwatch.observer/filing/0001558370-23-011550.md","text":"https://secwatch.observer/filing/0001558370-23-011550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/plx-20230628x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:34:29.673917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c0c15a196b4f83f1a3b538a02c263e887960d02","claim":"Protalix BioTherapeutics, Inc. shareholders approved Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan at the 2023-06-28 meeting.","evidence_excerpt":"(4) Adoption of amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of common stock available under the plan from 8,475,171 shares to 12,475,171 shares and to amend certain other terms of said plan ​ For ​ Against ​ Abstain Broker Non-Votes 25,811,597 6,921,213 108,665 8,872,021","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-28"}],"fact_type":"shareholder_vote"},{"claim_id":"4cd5f3d68d9b915765c4cac87b7eb801cd36cd76","claim":"Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers at the 2023-06-28 meeting.","evidence_excerpt":"(3) Approval, on a non-binding advisory basis, the frequency (every one, two or three years) that stockholders of the Company will have a non-binding, advisory vote on the compensation of the Company’s named executive officers ​ ​ One Year ​ Two Years ​ Three Years ​ Abstain Broker Non-Votes 30,261,982 600,162 825,319 1,154,012 8,872,021","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-28"}],"fact_type":"shareholder_vote"},{"claim_id":"4ff5cb99129f05da5b03a961634e24899aa7ad86","claim":"Protalix BioTherapeutics, Inc. shareholders approved Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2023-06-28 meeting.","evidence_excerpt":"(2) Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers ​ For ​ Against ​ Abstain Broker Non-Votes 26,186,630 4,269,510 491,310 8,872,021","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-28"}],"fact_type":"shareholder_vote"},{"claim_id":"6c1a1c8444022836c9e962526141d8bd8d5e8bd5","claim":"Protalix BioTherapeutics, Inc. shareholders approved Election of Directors at the 2023-06-28 meeting.","evidence_excerpt":"(1) Election of Directors ​ For ​ Withheld Broker Non-Votes Zeev Bronfeld 30,118,208 2,723,267 8,872,021 Dror Bashan 30,175,739 2,665,736 8,872,021 Amos Bar Shalev 30,118,524 2,722,951 8,872,021 Shmuel “Muli” Ben Zvi, Ph.D. 30,614,690 2,226,785 8,872,021 Pol F. Boudes, M.D. 30,619,760 2,221,715 8,872,021 Gwen A. Melincoff 30,517,556 2,323,919 8,872,021 Aharon Schwartz, Ph.D. 30,659,904 2,181,571 8,872,021","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-28"}],"fact_type":"shareholder_vote"},{"claim_id":"87c5a26968c22fdc262249c85e5b2933e455627b","claim":"Protalix BioTherapeutics, Inc. shareholders approved Approval of adjournment of the 2023 Annual Meeting to July 13, 2023 to provide additional time to solicit proxies for a charter amendment at the 2023-06-28 meeting.","evidence_excerpt":"The adjournment was approved by a vote of 39,819,471 shares of Common Stock, with no shares voting against the adjournment or abstaining","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-28"}],"fact_type":"shareholder_vote"},{"claim_id":"c8055c0078bbb308651e5d39ca2fce8dbfb7c7a5","claim":"Protalix BioTherapeutics, Inc. shareholders approved Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-28 meeting.","evidence_excerpt":"(5) Ratification of the appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International Limited For Against Abstain 36,781,844 2,683,094 354,533","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-28"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}